The analyst believes positive underlying fundamentals are relatively unchanged and become more of a focus as overhangs continue to resolve.

Sotera Health has maintained underlying HSD-LDD organic revenue growth and can still fund capacity expansions, notes Mishan.

Precisely, it has quantified seven ongoing projects across geographies and sterilization modalities and is working toward long-term ways to diversify its supply of Co-60. 

Price Action: SHC shares are trading higher by 3.3% to $18.59 on the last check Monday.